Remission Up for Mepolizumab in Eosinophilic Granulomatosis

Share this content:
Remission Up for Mepolizumab in Eosinophilic Granulomatosis
Remission Up for Mepolizumab in Eosinophilic Granulomatosis

THURSDAY, May 25, 2017 (HealthDay News) -- Mepolizumab is associated with significantly more weeks in remission than placebo among patients with eosinophilic granulomatosis with polyangiitis, according to a study published in the May 18 issue of the New England Journal of Medicine.

Michael E. Wechsler, M.D., from National Jewish Health in Denver, and colleagues conducted a multicenter phase 3 trial involving participants with relapsing or refractory eosinophilic granulomatosis with polyangiitis. In addition to standard care, participants were randomized to receive mepolizumab (68 patients) or placebo (68 patients) administered every four weeks for 52 weeks.

The researchers found that, compared with placebo, mepolizumab treatment correlated with significantly more accrued weeks of remission (28 versus 3 percent of participants had ≥24 weeks of accrued remission, respectively; odds ratio, 5.91) and a higher percentage of participants in remission at weeks 36 and 48 (32 versus 3 percent; odds ratio, 16.74). Remission did not occur in 47 and 81 percent of participants in the mepolizumab and placebo groups, respectively. The annualized relapse rate was 1.14 and 2.27 in the mepolizumab and placebo groups, respectively (rate ratio, 0.50). Overall, 44 and 7 percent of those taking mepolizumab and placebo had an average daily dose of prednisolone or prednisone of 4.0 mg or less per day during weeks 48 through 52 (odds ratio, 0.20).

"The results of our trial show an advance for patients with this rare disease," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including GlaxoSmithKline, which manufactures mepolizumab and funded the study.

Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease



Sign up for myCME e-newsletters




More in Home

Meds for Opioid Use Disorder May Reduce Mortality in OD Survivors

Meds for Opioid Use Disorder May Reduce Mortality ...

Minority of opioid overdose survivors receive MOUD; buprenorphine, MMT linked to reduced mortality

Pharmacists Are Well Placed to Improve Adult Vaccination Rates

Pharmacists Are Well Placed to Improve Adult Vaccination ...

Pharmacies can address cost barriers to vaccination by providing vaccines at lower cost

Single Blood Sample Test May Help ID Undiagnosed Diabetes

Single Blood Sample Test May Help ID Undiagnosed ...

Single-sample confirmatory definition associated with high positive predictive value

is free, fast, and customized just for you!




Already a member?

Sign In Now »